Most Popular
-
1
Actor Jung Woo-sung admits to being father of model Moon Ga-bi’s child
-
2
Wealthy parents ditch Korean passports to get kids into international school
-
3
Man convicted after binge eating to avoid military service
-
4
First snow to fall in Seoul on Wednesday
-
5
Industry experts predicts tough choices as NewJeans' ultimatum nears
-
6
Final push to forge UN treaty on plastic pollution set to begin in Busan
-
7
Nvidia CEO signals Samsung’s imminent shipment of AI chips
-
8
Korea to hold own memorial for forced labor victims, boycotting Japan’s
-
9
Opposition chief acquitted of instigating perjury
-
10
Job creation lowest on record among under-30s
[THE INVESTOR] Samsung BioLogics is expected to raise up to 2.25 trillion won (US$2.04 billion) through its planned initial public offering next month, which will be the third-largest stock sale in the country’s history.
According to a securities registration statement of Samsung Group’s biopharmaceutical contract manufacturing arm on Oct. 4, it will seek to sell some 16.54 million shares at 113,000 won to 136,000 won.
If the company prices its IPO at the top end of its proposed range, it could raise 2.249 trillion won.
According to a securities registration statement of Samsung Group’s biopharmaceutical contract manufacturing arm on Oct. 4, it will seek to sell some 16.54 million shares at 113,000 won to 136,000 won.
If the company prices its IPO at the top end of its proposed range, it could raise 2.249 trillion won.
